Adial Pharmaceuticals, Inc.
ADIL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001513525
In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Adial Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 11 | 17 | +6 |
| Shares | 59.1K | 266.5K | +207.3K (+350.6%) |
| Value | $164.2K | $495.3K | +$331.2K (+201.7%) |
New holders (6)
Institutions that held Adial Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 159,000 | $295.7K | 0.01% |
| Renaissance Technologies LLC | 23,200 | $43.0K | 0.00% |
| Susquehanna International Group, LLP | 14,789 | $27.5K | 0.00% |
| Tower Research Capital LLC (TRC) | 4,234 | $7.88K | 0.00% |
| JPMorgan Chase & Co | 2,500 | $4.65K | 0.00% |
| Focused Wealth Management, Inc | 549 | $1.02K | 0.00% |
Sold out (0)
Institutions that held Adial Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
None.